<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04290793</url>
  </required_header>
  <id_info>
    <org_study_id>HRHB-CB001</org_study_id>
    <nct_id>NCT04290793</nct_id>
  </id_info>
  <brief_title>Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER-2+ Breast Cancer</brief_title>
  <official_title>Neoadjuvant Chemotherapy With Pyrotinib, Epirubicin and Cyclophosphamide Followed by Taxanes and Trastuzumab for HER2+Breast Cancer: a Multicenter, Randomized, Open-label, Parallel-Group Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Hebei Medical University Fourth Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Hebei Medical University Fourth Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a prospective, open label, parallel controlled study to evaluate the efficacy and
      safety of neoadjuvant pyrotinib in HER2+ breast cancer patients
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">March 1, 2020</start_date>
  <completion_date type="Anticipated">March 1, 2024</completion_date>
  <primary_completion_date type="Anticipated">March 1, 2022</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pathological Complete Response rate(pCR)</measure>
    <time_frame>within 3 weeks after surgery</time_frame>
    <description>pathological complete response</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>2 years</time_frame>
    <description>Baseline to measured stable disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event Free Survival(EFS)</measure>
    <time_frame>3 years</time_frame>
    <description>Baseline to the occurrence of any event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival(DFS) Baseline to measured date of recurrence or death from any cause</measure>
    <time_frame>3 years</time_frame>
    <description>Baseline to measured date of recurrence or death from any cause</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>5 years</time_frame>
    <description>Baseline to measured date of death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">280</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>Experimental group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients will receive the test drug (Pyrotinib) combined with Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will only receive Epirubicin and Cyclophosphamide followed by Taxanes and Trastuzumab</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pyrotinib</intervention_name>
    <description>400mg administered as continuous oral once daily from the first day of the study</description>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epirubicin</intervention_name>
    <description>90mg/m^2 d1 iv Q2W for 4 cycles</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclophosphamide</intervention_name>
    <description>600 mg/m^2 d1 iv Q2W for 4 cycles</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Taxanes</intervention_name>
    <description>Albumin paclitaxel（125mg/m2 d1、8 iv Q3W for 4 Cycles）/Docetaxel(100mg/m2 d1 iv Q3W for 4 Cycles )</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Trastuzumab</intervention_name>
    <description>the first cycle is a loading dose of 8 mg / kg, followed by 6 mg / kg. Iv Q3W for 1 year</description>
    <arm_group_label>Control group</arm_group_label>
    <arm_group_label>Experimental group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Female breast cancer patients at the age of &gt;= 18 years and &lt;= 65 years who received
             first treatment；

          2. Pathologically confirmed HER2-positive invasive breast cancer（which is defined as the
             immunohistochemistry score of &gt; 10% immunoreactive cells being 3+ or in situ
             hybridization results showing HER2 gene amplification），regardless of hormone receptor
             status (ER and PR)；

          3. According to the 2019 CSCO BC guidelines: When HER-2 positive is used as the standard
             for preoperative neoadjuvant therapy for breast cancer, the tumor is larger than 2 cm；

          4. The Eastern Tumor Collaborative Group (ECOG) has a physical status score of ≤1；

          5. The functional level of the main organs must meet the following requirements ： 1)
             blood routine test: hemoglobin (Hb) ≥ 90g/L;Neutrophils (ANC) ≥ 1.5 × 10^9/L; platelet
             count (PLT) ≥ 90 × 10^9/L; 2) Blood biochemistry: Total bilirubin (TBIL) ≤ 1.5 upper
             limit of normal value (ULN); Alanine aminotransferase (ALT) and aspartate
             aminotransferase (AST) ≤ 1.5 × ULN; alkaline phosphatase ≤ 2.5 × ULN; Urea nitrogen
             (BUN) and creatinine (Cr) ≤ 1.5 × ULN; 3) Heart color ultrasound: Left ventricular
             ejection fraction (LVEF) ≥ 55%;

          6. Women of childbearing age, tested negative for serum pregnancy test 7 days before
             randomization，and willing to use appropriate methods during the trial and within 8
             weeks after the last administration of the test drug;

          7. A volunteer to participate in the study; provision of written informed consent; good
             compliance and willing to cooperate during the follow-up.

        Exclusion Criteria:

          1. Known history of hypersensitivity to pyrotinib or any of it components;

          2. Patients have previously received antitumor treatment or radiation therapy for any
             malignant tumor (except for cervical carcinoma in situ and basal cell carcinoma that
             have been cured);

          3. Patients underwent major breast cancer-free surgery within 4 weeks and have not fully
             recovered;

          4. Subjects that are unable to swallow tablets,intestinal obstruction or dysfunction of
             gastrointestinal absorption;

          5. Patients with severe heart disease or discomfort who cannot be treated;

          6. The patient suffers from mental illness or psychotropic substance abuse and cannot
             cooperate;

          7. Pregnant or lactating women;

          8. Less than 4 weeks from the last clinical trial;

          9. Patients participating in other clinical trials at the same time

         10. The researchers think inappropriate.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>YUNJIANG LIU, PHD.</last_name>
    <phone>86095588</phone>
    <email>lyj818326@126.com</email>
  </overall_contact>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 27, 2020</study_first_submitted>
  <study_first_submitted_qc>February 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">March 2, 2020</study_first_posted>
  <last_update_submitted>February 27, 2020</last_update_submitted>
  <last_update_submitted_qc>February 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 2, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Hebei Medical University Fourth Hospital</investigator_affiliation>
    <investigator_full_name>Liu Yunjiang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Trastuzumab</mesh_term>
    <mesh_term>Epirubicin</mesh_term>
    <mesh_term>Taxane</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

